Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. France
  4. Euronext Paris
  5. Poxel
  6. News
  7. Summary
    POXEL   FR0012432516

POXEL

(POXEL)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Poxel : Corporate Presentation

06/01/2021 | 08:51am EDT

Corporate Presentation

June 2021

Disclaimer

Some of the statements contained in this presentation constitute forward-looking statements. Statements that are not historical facts are forward-looking statements. Forward-looking statements generally can be identified by the use of forward- looking terminology such as "may", "will", "expect", "intend", "estimate", "anticipate", "believe", "continue" or similar terminology. These statements are based on the Company's current strategy, plans, objectives, assumptions, estimates and projections. Investors should therefore not place undue reliance on those statements. The Company makes no representation, warranty or prediction that the results anticipated by such forward-looking statements will be achieved, and such forward-looking statements represent, in each case, only one of many possible scenarios and should not be viewed as the most likely or standard scenario. Forward-looking statements speak only as of the date that they are made and the Company does not undertake to update any forward-looking statements in light of new information or future events. Forward- looking statements involve inherent risks and uncertainties. The Company cautions that a number of important factors could cause actual results to differ materially from those contained in any forward-looking statement.

In the context of the COVID-19 outbreak, which was declared a pandemic by the World Health Organization (WHO) on March 12, 2020, the Company is regularly reviewing the impact of the outbreak on its business. As of the date of this presentation, and based on publicly available information, the Company has not identified the occurrence of any material negative effect on its business due to the COVID-19 pandemic that remains unresolved. However, the Company anticipates that the COVID-19 pandemic could have further material negative impact on its business operations. The worldwide impact of COVID-19 may notably affect the Company's internal organization and efficiency, particularly in countries where it operates and where confinement measures are implemented by the authorities. In addition, COVID-19 may impact market conditions and the Company's ability to seek additional funding or enter into partnerships. Particularly, delays in the supply of drug substance or drug products, in the initiation or the timing of results of preclinical and/or clinical trials, as well as delays linked to the responsiveness of regulatory authorities could occur, which could potentially have an impact on the Company's development programs and partnered programs. The Company will continue to actively monitor the situation.

2

Poxel's Mission and Vision

To discover, develop and commercialize innovative therapies for patients suffering from serious chronic diseases with underlying metabolic pathophysiology

acetyl CoA

METABOLIC

INFLAMMATION

DISORDERS

(cellular energy

TISSUE

homeostasis

DEGENERATION

imbalances)

& CELL DEATH

apoptosis,

necrosis

3

Three Pillars of Poxel's Strategy

First-in-Class Programs Leading to Key Value Inflection Points

Unique platforms

Partnered in Asia1 with diabetes

Oral First-in-

AMPK

D-TZD

Pipeline

Platform

Platform

expansion

External

market leader in Japan

Class Phase 2

into new

Sumitomo Dainippon Pharma

Opportunities

Programs

indications

Imeglimin

PXL770

Next

Generation

PXL065

Programs

*X-linked

adrenoleukodystrophy &

adrenomyeloneuropathy (AMN)

Expected approval in 20212

Phase 2 biopsy data for both

New clinical programs in

triggering milestones

programs in 2022-2023

next 12-24 months

Phase 3 ready partnership

Combination potential

Further strengthening

opportunity in US/EUR

product pipeline

1. Including: Japan, China, South Korea, Taiwan, Indonesia, Vietnam, Thailand, Malaysia, the Philippines, Singapore, Myanmar, Cambodia, and Laos. 2. Sumitomo fiscal year April-March.

4

Poxel Platforms and Molecules Target Key Nodes that Regulate Cellular Energy Homeostasis

Multiple Entry Points Available to Intervene in Metabolic Diseases

NASH Other

AMP-activated Protein Kinase (AMPK)

Activator Platform

cellular energy sensor :

reduces liver fat, increases insulin sensitivity, decreases inflammation

NASH Other

Deuterium-Stabilized TZD* Platform non-genomic pathway modulators of mitochondrial pyruvate carrier -

  1. key fuel gate-keeper : promotes fat utilization, increases insulin
    sensitivity, decreases inflammation

T2D

Imeglimin- modulates mitochondrial respiratory chain (MRC), cell's energy

producing machine: improved islet β-

cell function; insulin sensitization; cardiorenal benefits; several other disease opportunities

AMPK

MPC

Pyruvate

Activates

Inhibits

catabolic

inflammation

pathways

apoptosis

T

Inhibits anabolic

pathways

* Thiazolidinediones (glitazones) - operate via PPARγ and non-genomic pathways including MPC (mitochondrial pyruvate carrier).

5

Acetyl

Co-A

TCA

ATP

cycle

NADH

FADH2

MRC

MITOCHONDRIA

This is an excerpt of the original content. To continue reading it, access the original document here.

Disclaimer

Poxel SA published this content on 01 June 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 01 June 2021 12:50:03 UTC.


ę Publicnow 2021
All news about POXEL
07/26POXEL : Corporate Profile July 2021
PU
07/22GLOBAL MARKETS LIVE : AT&T, American Airlines, Biogen, Netflix, ABB...
07/21Poxel S.A. Reports Revenue Results for the Second Quarter and Six Months Ende..
CI
07/13POXEL : Corporate Profile July 2021
PU
07/13POXEL : Corporate Presentation
PU
07/12GLOBAL MARKETS LIVE : Volkswagen, Amazon, Credit Suisse, Tesla, Walmart...
07/12Poxel S.A. Announces New Strategic Direction with Increasing Focus on Rare Me..
CI
06/25POXEL : Agreement 2021
PU
06/25POXEL : présente les résultats de deux études cliniques sur son activateur direc..
PU
06/25Poxel Presents Results of Two Clinical Studies on Its Direct Amp Kinase Activ..
CI
More news
Financials
Sales 2021 22,8 M 26,9 M 26,9 M
Net income 2021 -32,3 M -38,2 M -38,2 M
Net cash 2021 8,20 M 9,70 M 9,70 M
P/E ratio 2021 -5,22x
Yield 2021 -
Capitalization 168 M 199 M 199 M
EV / Sales 2021 7,02x
EV / Sales 2022 8,34x
Nbr of Employees 50
Free-Float 80,3%
Chart POXEL
Duration : Period :
Poxel Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends POXEL
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 4
Last Close Price 5,87 €
Average target price 15,95 €
Spread / Average Target 172%
EPS Revisions
Managers and Directors
Thomas Kuhn Chief Executive Officer & Director
Anne Renevot Chief Financial Officer & Executive Vice President
Pierre Legault Chairman
Sophie Hallakou-Bozec Senior Vice President-Research & Development
Takashi Kaneko Senior Vice President-Medical
Sector and Competitors
1st jan.Capi. (M$)
POXEL-7.78%199
GILEAD SCIENCES, INC.18.31%86 563
BIONTECH SE248.38%69 138
WUXI APPTEC CO., LTD.28.80%67 035
REGENERON PHARMACEUTICALS20.26%59 833
VERTEX PHARMACEUTICALS-14.17%51 496